Triangle Park (Quezon City)

Highwoods Announces Recent Disposition Activity

Retrieved on: 
Thursday, April 4, 2024
GAAP, Research Triangle Park, HIW, Triangle Park (Quezon City), Sale, UNC Rex Healthcare, Bank

RALEIGH, N.C., April 04, 2024 (GLOBE NEWSWIRE) -- Highwoods Properties, Inc. (NYSE:HIW) has sold in a series of transactions non-core properties in Raleigh for combined gross proceeds of $79.4 million.

Key Points: 
  • RALEIGH, N.C., April 04, 2024 (GLOBE NEWSWIRE) -- Highwoods Properties, Inc. (NYSE:HIW) has sold in a series of transactions non-core properties in Raleigh for combined gross proceeds of $79.4 million.
  • Gross proceeds from dispositions closed in the first quarter of 2024 totaled $16.9 million with the remainder closing early in the second quarter.
  • As part of the sale of one building, the Company provided $6.2 million in non-recourse first mortgage seller financing.
  • The note is scheduled to mature in February 2025, but can be prepaid without penalty at any time prior to maturity.

Asensus Surgical, Inc. Reports Operating and Financial Results for the Fourth Quarter 2023 and Full Year 2023

Retrieved on: 
Thursday, March 21, 2024
Flex, Growth, Urology, Communication, Patient, Telephone, Sale, TRUST, General surgery, Software, Security (finance), Motion, Freezing, LUNA, Surgeon, Bank statement, Gynaecology, Investment, Annual report, Triangle Park (Quezon City), GAAP, File, Optimism, FDA, CIS, Health, Nursing

“As we look at 2024, there's a sense of optimism as we aim to hit significant milestones in the coming quarters.

Key Points: 
  • “As we look at 2024, there's a sense of optimism as we aim to hit significant milestones in the coming quarters.
  • During the fourth quarter of 2023, the Company initiated five new Senhance Surgical System placements, one in Germany, one in Romania, two in the CIS region and one in Japan at Nagoya University Hospital.
  • In 2023, surgeons performed over 3,550 procedures utilizing the Senhance System, representing a 13% increase over the previous year.
  • In addition to regulatory milestones, the Company has introduced four Senhance System programs dedicated to pediatric departments in the U.S. and internationally.

Mattamy announces new homes for sale in historic Angier, North Carolina

Retrieved on: 
Wednesday, March 13, 2024
Community, NC-55, Tennis, Stonebarrow, Sale, Town, University, Campbell University, Raven Rock State Park, Triangle Park (Quezon City), Mattamy Homes, Bath, Recreation

RALEIGH, N.C., March 13, 2024 /PRNewswire/ - Mattamy Homes , North America's largest privately owned homebuilder, is pleased to announce that new homes are now open for sale at Riverfall , located in historic and charming Angier, North Carolina .

Key Points: 
  • RALEIGH, N.C., March 13, 2024 /PRNewswire/ - Mattamy Homes , North America's largest privately owned homebuilder, is pleased to announce that new homes are now open for sale at Riverfall , located in historic and charming Angier, North Carolina .
  • Construction on Mattamy's first release of quick move-in homes in Riverfall will be completed in June.
  • Nearby major universities include Campbell University, The University of North Carolina-Chapel Hill, North Carolina State, Duke and more.
  • Riverfall joins Mattamy Homes' Providence Creek and Stonebarrow communities in Harnett County.

LifeScience Logistics Enhances Offerings with Innovative Sampling & Dispensing Suite at Raleigh-Durham Facility

Retrieved on: 
Tuesday, March 5, 2024
Triangle Park (Quezon City), Clinical trial, LSL, Research Triangle, 3PL, Research, Environment, Pharmaceutical industry

Its new ISO Grade C cleanroom suite for pharmaceutical sampling and dispensing will support efficient quality control testing, research and development, and clinical trial efforts for LSL’s partners.

Key Points: 
  • Its new ISO Grade C cleanroom suite for pharmaceutical sampling and dispensing will support efficient quality control testing, research and development, and clinical trial efforts for LSL’s partners.
  • This state-of-the-art sampling and dispensing suite will enable Research Triangle Park-area pharmaceutical manufacturers to not only store and distribute products via LSL, but also handle their sampling and dispensing needs under one roof.
  • The addition of our Raleigh-Durham cleanroom suite is one of the many ways we continue to expand our service offerings and respond to the evolution of healthcare supply chain demands,” David Cheetham, CEO of LifeScience Logistics, stated.
  • “Sampling [in particular] is a critical step in ensuring the quality of pharmaceutical products,” Cheetham says.

Merakris Therapeutics to Release Final Part 1 Data From Phase 2 Multicenter Investigational Drug Study for Dermacyte® Liquid

Retrieved on: 
Tuesday, February 20, 2024
Research Triangle Park, Triangle Park (Quezon City), FDA, Part, Vein, Leg, Skin, Conference, Veterans' affairs, Safety, Therapy, Patent, Part 1, Patient, PST, Clinical trial, Ulcer, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Merakris Therapeutics announced that it will present encouraging safety and efficacy data from the first of a two-part Phase 2 multi-center clinical study of its investigational wound care drug, Dermacyte® Amniotic Wound Care Liquid.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Merakris Therapeutics announced that it will present encouraging safety and efficacy data from the first of a two-part Phase 2 multi-center clinical study of its investigational wound care drug, Dermacyte® Amniotic Wound Care Liquid.
  • The study consented 12 patients who were assessed for eligibility to receive the investigational drug treatment.
  • Preliminary data indicate an 84% average reduction in ulcer surface area for the 9 patients completing the 12-week study.
  • These data are being analyzed by the Merakris scientific team and an independent data safety and monitoring committee and will inform the design of Part 2 of the multi-center clinical study.

First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure

Retrieved on: 
Tuesday, February 13, 2024
Heart, Gene, NYHA, Doctor of Philosophy, Triangle Park (Quezon City), News, Ageing, Mass, Cardiomyopathy, CHF, Executive Committee, Heart failure, Safety, Bayer, Patient, Guideline, Disease, Phase, Committee, Pharmaceutical industry

Berlin, Germany and Research Triangle Park, NC, USA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media

Key Points: 
  • Berlin, Germany and Research Triangle Park, NC, USA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media
    Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that the first patient has been randomized in GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase II trial of AB-1002 (also known as NAN-101) for the treatment of congestive heart failure (CHF).
  • “GenePHIT will evaluate the safety and efficacy of AB-1002 in the largest number of patients to date and improve our understanding of gene therapy overall for the treatment of congestive heart failure.
  • “The enrollment of this first patient in the Phase II trial represents the culmination of many years of dedicated research and development in all aspects of cardiac gene therapy for congestive heart failure.
  • AB-1002 is manufactured by Viralgen Vector Core, S.L., a wholly owned and independently operated subsidiary of AskBio.

Preterm Births Linked to 'Hormone Disruptor' Chemicals May Cost United States Billions

Retrieved on: 
Tuesday, February 6, 2024
ECHO, University, Columbia University, NYU, Cosmetics, Phthalate, Bangladesh Technical Education Board, Champaign–Urbana metropolitan area, Wayne State University, Lancet, NYU Langone Health, Food, National Institutes of Health, DEHP, MPH, Emory University, Woman, Johns Hopkins University, Population health, MPP, Blood, DIDP, Northeastern University, Infant, Risk, Doctor of Philosophy, Rutgers University, Cancer, Gestational age, Triangle Park (Quezon City), Racism, Mother, Research, Obesity, Preterm birth, RTI International, The Lancet, Pregnancy, Doctor of Science, Dartmouth College, Diabetes, Pennsylvania State University, Urine, Hormone, Achievement Medal, Pediatrics, Dietary supplement

Then, the team looked for associations between these metabolite levels and preterm births.

Key Points: 
  • Then, the team looked for associations between these metabolite levels and preterm births.
  • "Otherwise, investigators are likely going to find the same study results in another few years about the next group of chemicals used as replacements."
  • California, among a few states, has banned some use of phthalates in consumer products, as have European Union member states.
  • Trasande cautions that further research is needed to better understand the specific mechanisms behind the link between phthalate exposure and preterm birth.

Alcami Opens New Advanced Pharma Storage and Services Facility in Central North Carolina

Retrieved on: 
Wednesday, January 24, 2024
Temperature, CGMP, RTP, Tissue, Golden Joystick Awards, GMP, Acquisition, Triangle Park (Quezon City), ICH, Research Triangle Park, CDMO, Vaccine

DURHAM, N.C., Jan. 24, 2024 /PRNewswire/ -- Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), today announced the opening of its new 65,000 ft² state-of-the-art Pharma Storage and Services operations facility in Garner, North Carolina close to the Research Triangle Park biotech and pharma hub.

Key Points: 
  • - Ambient storage now open for shipments, with stability storage, aliquoting and cold storage phasing in later in 2024
    DURHAM, N.C., Jan. 24, 2024 /PRNewswire/ -- Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), today announced the opening of its new 65,000 ft² state-of-the-art Pharma Storage and Services operations facility in Garner, North Carolina close to the Research Triangle Park biotech and pharma hub.
  • The new central North Carolina facility, now accepting client pallets for ambient/controlled room temperature storage, adds to the company's network of GMP storage facilities across North America.
  • Part of the company's intentional strategy to strengthen its pharma storage and services business with key locations to streamline operations for biotech and pharma clients, the site will phase in stability storage and aliquoting, followed by cold storage later this year.
  • "As pressures intensify to outsource GMP storage of biopharmaceutical materials and products for cost savings that can fuel clients' R&D and other projects, our new RTP pharma storage and services facility is well-positioned to fill this previously unmet market demand," said Laurent Boer, President, Alcami Pharma Storage and Services.

Asensus Surgical Provides Preliminary 2023 Year-End Corporate Update

Retrieved on: 
Monday, January 8, 2024
Dots, General surgery, Freezing, Urology, Face, Sale, Software, CIS, Animation, FDA, Surgeon, Triangle Park (Quezon City), BBC, Health, Intelligence, Motion, 3D, ISU, Growth, Investment, TRUST, Patient, Flex, MedTech Europe, LUNA, NVIDIA, Gynaecology, Communication, Nursing

RESEARCH TRIANGLE PARK, N.C., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient, provided a preliminary 2023 year-end corporate update.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient, provided a preliminary 2023 year-end corporate update.
  • In 2023, the Company initiated eight new Senhance Surgical System placements: one in the United States, one in Germany, three in Japan, one in Romania, and two in the CIS region.
  • In 2023, surgeons performed over 3,550 procedures utilizing the Senhance System, representing a 14% increase over the previous year.
  • For the quarter ending on December 31, 2023, the Company estimates preliminary unaudited revenue of approximately $5.1 - $5.7 million.

LifeScience Logistics Expands Raleigh-Durham Presence with Second Pharmaceutical Storage and Distribution Facility for Pharmaceutical and Medical Device Manufacturers

Retrieved on: 
Friday, January 5, 2024
Research Triangle, Research Triangle Park, API, Business, FDA, LSL, Triangle Park (Quezon City), Heart, Business development, SF, Warehouse

This facility will be LSL’s 17th strategic location across the United States and the second location added to the Raleigh-Durham hub.

Key Points: 
  • This facility will be LSL’s 17th strategic location across the United States and the second location added to the Raleigh-Durham hub.
  • This innovative 249,600 SF facility, located in the heart of Research Triangle Park, will expand LSL’s capacity to provide FDA-registered, cGMP-compliant, temperature-controlled storage and end-to-end 3PL solutions to pharmaceutical and medical device manufacturers operating in the Raleigh-Durham area.
  • “We decided to build an additional facility to support the unprecedented demand for both pharmaceutical and medical device temperature-controlled storage and distribution in the Raleigh-Durham region.”
    LSL anticipates strong demand for the solutions offered in their latest Raleigh-Durham facility.
  • The new location will ensure the safe and compliant storage of finished goods, API, raw materials, and packaging materials.